Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance trabectedin versus observation after first-line doxorubicin in advanced or metastatic soft tissue sarcoma
2016-003535-38Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in soft tissue sarcoma (STS) comparing Maintenance trabectedin with Observation only (2 arms). Primary endpoint: Progression-free survival. Started Apr 2017; status: terminated.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2016-003535-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003535-38.